Welcome to our dedicated page for Metagenomi Therapeutics news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi Therapeutics stock.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a biotechnology company focused on in vivo genome editing and precision genetic medicines. Its news flow centers on progress across its proprietary gene editing toolbox and its therapeutic pipeline, particularly the MGX-001 program for hemophilia A and additional programs in secreted protein deficiencies and cardiometabolic diseases.
News updates for MGX often highlight preclinical data releases, such as non-human primate studies demonstrating durable and therapeutically relevant factor VIII (FVIII) activity for MGX-001, dose range finding results, and safety observations that inform proposed clinical dosing strategies. The company also issues press releases on pipeline prioritization, describing decisions to focus resources on later-stage preclinical assets and its most advanced gene-editing capabilities.
Investors and observers can expect coverage of collaboration milestones, including developments in Metagenomi’s partnership with Ionis Pharmaceuticals on cardiometabolic targets like APOC3. Scientific and medical conference participation is another recurring theme, with the company presenting data at meetings such as the American Society of Gene & Cell Therapy (ASGCT), TIDES USA, and other conferences where it shares advances in compact nucleases, CRISPR-associated transposases (CAST), and AI-guided metagenomic discovery.
MGX news also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, organizational changes, board appointments, and the corporate name change to Metagenomi Therapeutics, Inc. For those following MGX, this news page provides a consolidated view of scientific progress, collaboration updates, and corporate developments reported in press releases and related communications.
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. The session is scheduled for Thursday, September 10, 2026, at 12:45 p.m. ET and will be accessible via the Investors “News & Events” page on the company’s website.
Metagenomi Therapeutics (Nasdaq: MGX) reported second quarter 2026 results and business updates, highlighting progress on lead in vivo genome-editing candidate MGX-001 for hemophilia A. IND-enabling studies, including GLP toxicity, are expected to complete by end of 3Q 2026, with an IND filing planned for 4Q 2026 and potential clinical trial initiation in 2027, subject to regulatory clearance.
The company reported $120.7 million in cash, cash equivalents and marketable securities as of June 30, 2026, and anticipates runway through 4Q 2027. For 2Q 2026, R&D expenses were $22.5 million (flat year over year), G&A was $6.0 million (down from $7.0 million), and net loss was $27.5 million versus $19.9 million a year earlier. Collaboration revenue was negative at $(0.3) million compared with $8.5 million in 2Q 2025. Cash and investments declined from $160.8 million at December 31, 2025.
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 7:35 a.m. ET. The presentation will be accessible via the Investors section of the company’s website.
Metagenomi Therapeutics (Nasdaq: MGX) reported Q1 2026 business updates and financial results. MGX-001 for hemophilia A remains on track for regulatory submissions, including an IND in 4Q 2026, with clinical trials expected in 2027 pending clearance.
The company highlighted a Nature Structural & Molecular Biology publication on MG119-28, a compact CRISPR nuclease with enhanced editing efficiency. Cash, cash equivalents, and marketable securities totaled $140.2 million as of March 31, 2026, with runway anticipated through 4Q 2027. R&D expenses were $19.3 million and G&A expenses were $6.5 million for Q1 2026.
Metagenomi (Nasdaq: MGX) announced a Nature Structural & Molecular Biology publication describing MG119-28 (Al3Cas12f), a compact CRISPR nuclease with improved genome editing efficiency versus prior compact nucleases.
The study attributes enhanced performance to greater protein structural stability and a more stable guide RNA, and reports engineering that improves activity across multiple targets. Prior in vivo work showed 64% Atxn2 protein knockdown in mice after a single AAV delivering MG119-28 and a guide.
Metagenomi (Nasdaq: MGX) reported full-year 2025 results and business updates, highlighting preclinical curative FVIII activity for MGX-001 in non-human primates, completion of a pre-IND meeting, and a target IND submission in 4Q 2026. Cash, equivalents, and marketable securities totaled $160.8 million as of December 31, 2025, with runway expected through 4Q 2027. The company also announced a corporate name change to Metagenomi Therapeutics, Inc., presented proof-of-concept data for antithrombin deficiency, and advanced a cardiometabolic collaboration target with Ionis Pharmaceuticals.
Metagenomi (Nasdaq: MGX) announced that Jian Irish, Ph.D., M.B.A., President and CEO, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026 at 11:10 a.m. ET.
According to Metagenomi, the presentation will be available on the company’s Investors "News & Events" page following the event.
Metagenomi Therapeutics (Nasdaq: MGX) completed a corporate name change and outlined 2025 achievements plus a 2026 outlook focused on advancing lead program MGX-001 for hemophilia A. Key reported facts: MGX-001 produced durable factor VIII (FVIII) activity in non-human primates over ~19 months, showed no identifiable off-target editing in orthogonal assays, and completed a pre-IND meeting in 4Q 2025. The company expects to submit an IND/CTA in 4Q 2026, initiate first-in-human studies in 2027, and anticipates cash runway into 4Q 2027.
Metagenomi (Nasdaq: MGX) will present new preclinical data supporting APOC3 as the third collaboration target with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” on Dec 8-10, 2025 in Boston.
Presentation title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia. Presenter: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi. Date/time: Monday, December 8, 2025 at 2:45 p.m. EST. The talk covers preclinical evidence supporting the APOC3 target in the Ionis collaboration.
Metagenomi (Nasdaq: MGX) announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:30 a.m. GMT.
A live webcast of the presentation will be available in the company's investor section at https://ir.metagenomi.co/, and a replay will be posted there for a limited time.